RaySearch Laboratories AB

  • Market Cap: Small Cap
  • Industry: Software Products
  • ISIN: SE0000135485
SEK
225.00
-2 (-0.88%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About RaySearch Laboratories AB stock-summary
stock-summary
RaySearch Laboratories AB
Software Products
RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
Company Coordinates stock-summary
Company Details
Sveavagen 44, Box 3297 , STOCKHOLM None : 103 65
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Lars Wollung
Independent Chairman of the Board
Mr. Johan Lof
Chief Executive Officer, President, Director
Mr. Carl Bergendal
Independent Director
Ms. Johanna Oberg
Independent Director
Ms. Britta Wallgren
Independent Director
Dr. Hans Wigzell
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
305 Million
(Quarterly Results - Jun 2025)
Net Profit:
31 Million
stock-summary
Industry

Software Products

stock-summary
Market cap

SEK 6,499 Million (Small Cap)

stock-summary
P/E

42.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.23%

stock-summary
Debt Equity

-0.27

stock-summary
Return on Equity

23.84%

stock-summary
Price to Book

7.07